Conference
Pharmacologic insights into the future of trastuzumab
Abstract
A combination of factors has been responsible for improvements in cancer survival and cure rates. In addition to new therapies with novel/genetic targets, these include improvements in drug delivery, new schedules/sequencing of drug administration and the identification of combination therapies with greater activity/dose density than existing regimens. The recognition that such criteria can affect treatment outcome has led to their …
Authors
Leyland-Jones B; Arnold A; Gelmon K; Verma S; Ayoub J-P; Seidman A; Dias R; Howell J; Rakhit A
Volume
12
Pagination
pp. s43-s47
Publisher
Elsevier
Publication Date
2001
DOI
10.1093/annonc/12.suppl_1.s43
Conference proceedings
Annals of Oncology
ISSN
0923-7534